Oncolytics Biotech (TSE:ONC) Sets New 52-Week Low – Here’s What Happened

Oncolytics Biotech Inc. (TSE:ONC)’s stock price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.98 and last traded at C$1.00, with a volume of 139671 shares traded. The stock had previously closed at C$1.07.

Wall Street Analysts Forecast Growth

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Up 2.9 %

The firm’s 50-day simple moving average is C$1.23 and its two-hundred day simple moving average is C$1.36. The stock has a market cap of C$80.70 million, a price-to-earnings ratio of -2.76 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99.

Oncolytics Biotech (TSE:ONC) last announced its quarterly earnings data on Tuesday, November 12th. The company reported C($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C($0.11) by C($0.01). During the same quarter in the previous year, the company earned ($0.14) EPS. On average, sell-side analysts expect that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.